Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 32

Articles by Marisa Woutersen

Align Technology notches another win in escalating clear aligner feud
MedTech
Align Technology notches another win in escalating clear aligner feud
The US clear aligner giant has dealt another blow to a Chinese rival, securing an infringement ruling at the UPC as the pair wage a growing patent dispute across Europe, the US and China.   19 October 2026
Guardant loses second patent challenge to TwinStrand amid $245m damages fallout
Biotech
Guardant loses second patent challenge to TwinStrand amid $245m damages fallout
All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.   16 October 2026
Boehringer and Dr Reddy’s spar over plausibility as trial wraps up
Pharma
Boehringer and Dr Reddy’s spar over plausibility as trial wraps up
A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.   15 October 2026
Careers
Haynes Boone expands in California with new office
Growing demand from life sciences and healthcare clients prompts an expansion in California, bringing the firm closer to biotechnology companies, research institutions and key courts for its Southern California litigators.   14 October 2026
Pharma
Accord’s generic hopes dashed in cyanide antidote ruling
Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.   14 October 2026
Pharma
Novo’s semaglutide protection weakens after European ruling
Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.   13 October 2026
Pharma
MSD’s Keytruda hit by eight-country ban across Europe
Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations.   8 October 2026
Careers
Foley Hoag adds two partners in Denver expansion
The firm has snapped up IP partners from Sheridan Ross as it ramps up its presence in Denver and targets growing demand from life sciences and technology clients.   8 October 2026
In-house counsel
WATCH: LEO Pharma head of IP rights on doing more with less
With resources under pressure, the Danish company’s IP leader explains how AI, smarter prioritisation and close business ties can help IP teams boost their impact.   7 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.   6 October 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.